BRISTOL MYERS SQUIBB CO

BMY

BRISTOL MYERS SQUIBB CO

BMY

Insider Sentiment (TTM):

Last Purchase:2025-04-25Last Sale:2026-04-01Shares Purchased (TTM):0Shares Sold (TTM):86,000

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:1,435,643,223Shares Outstanding:2,038,000,000Institutional Ownership Pct.:70.44%

Earnings Market Reaction:

Filing Date:2026-07-30Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Companies in Pharmaceutical Preparations

LLY JNJ ABBV MRK ABT PFE

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Cash And Cash Equivalents At Carrying Value	8,722	9,574	10,209	15,726	12,599	10,875	10,346	7,890	6,293	9,330	11,464	7,514
Marketable Securities Current	-	-	-	-	-	-	-	-	-	-	-	171
Available For Sale Securities Debt Securities Curr…	2,345	912	464	776	1,004	907	513	204	360	340	816	-
Receivables Net Current	10,553	9,368	11,414	11,422	11,415	10,801	10,747	11,026	11,423	10,447	10,921	10,304
Assets Current
Assets Current	28,579	27,208	29,390	35,630	33,222	30,783	29,780	28,075	26,890	28,669	31,770	27,632
Inventory Net	2,737	2,756	2,690	2,758	2,737	2,666	2,557	3,332	3,077	2,985	2,662	2,436
Other Assets Current	4,222	4,597	4,613	4,948	5,466	5,534	5,617	5,623	5,737	5,567	5,907	7,207
Property Plant And Equipment Net	7,791	7,658	7,543	7,349	7,373	7,213	7,136	6,903	6,845	6,750	6,646	6,481
Goodwill	21,740	21,740	21,754	21,745	21,776	21,737	21,719	21,751	21,732	21,738	21,169	21,147
Intangible Assets Net Excluding Goodwill	17,387	18,244	19,103	20,465	21,378	22,486	23,307	26,964	29,428	32,760	27,072	28,950
Deferred Income Tax Assets Net	5,362	5,176	5,378	4,961	4,647	3,997	4,236	3,609	3,323	2,723	2,768	1,514
Marketable Securities	-	-	-	-	-	-	-	-	-	-	-	325
Available For Sale Securities Debt Securities Nonc…	397	366	396	406	346	344	320	324	357	367	364	-
Other Assets Noncurrent	6,378	6,082	6,474	6,332	5,936	5,866	6,105	6,044	6,071	6,024	5,370	5,214
Assets	87,634	86,476	90,038	96,889	94,676	92,427	92,603	93,670	94,646	99,031	95,159	91,263
Liabilities
Debt Current	1,027	2,308	2,261	4,509	4,715	3,554	2,046	1,078	3,531	6,190	3,119	5,467
Accounts Payable Current	4,158	4,234	3,575	4,288	5,427	4,002	3,602	3,469	3,751	3,539	3,259	2,813
Liabilities Current
Liabilities Current	18,659	19,158	23,417	28,136	27,528	24,070	23,774	22,638	23,265	25,822	22,262	23,462
Other Liabilities Current	13,474	12,616	17,581	19,339	17,386	16,514	18,126	18,091	15,983	16,093	15,884	15,182
Deferred Income Tax Liabilities Net	222	211	222	225	247	276	369	430	461	442	338	399
Long Term Debt Noncurrent	42,093	42,152	42,850	44,469	44,470	46,157	47,603	48,674	48,858	49,487	36,653	32,137
Other Liabilities Noncurrent	4,341	4,853	5,043	5,459	4,942	4,477	4,469	4,728	4,993	6,732	6,421	6,203
Liabilities	65,315	66,374	71,533	78,289	77,187	74,979	76,215	76,470	77,577	82,483	65,674	62,201
Stockholders Equity Inclu…
Preferred Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Value Outstanding	292	292	292	292	292	292	292	292	292	292	292	292
Additional Paid In Capital	46,504	46,374	46,387	46,265	46,134	46,011	46,024	45,896	45,766	45,655	45,684	44,849
Stockholders Equity
Stockholders Equity	22,319	20,068	18,473	18,600	17,489	17,448	16,335	17,142	17,069	16,490	29,430	29,062
Accumulated Other Comprehensive Income Loss Net Of…	-1,290	-1,370	-1,524	-1,513	-1,554	-1,424	-1,238	-1,468	-1,456	-1,400	-1,546	-1,286
Retained Earnings Accumulated Deficit	20,316	18,287	16,896	17,093	16,154	16,106	14,912	16,097	16,103	15,640	28,766	28,218
Treasury Stock Common Value	-43,504	-43,515	-43,579	-43,586	-43,590	-43,597	-43,655	-43,675	-43,690	-43,697	-43,766	-43,075
Minority Interest	0	34	33	48	54	59	53	58	54	58	55	64
Liabilities And Stockholders Equity	87,634	86,476	90,038	96,889	94,676	92,427	92,603	93,670	94,646	99,031	95,159	91,263
Preferred Stock Dividend Rate Per Dollar Amount	-	-	0	-	-	-	0	-	-	-	0	-
Preferred Stock Par Or Stated Value Per Share	-	-	1	-	-	-	1	-	-	-	1	-
Preferred Stock Shares Authorized	-	-	10	-	-	-	10	-	-	-	10	-
Preferred Stock Shares Issued	-	-	0	-	-	-	0	-	-	-	0	-
Preferred Stock Shares Outstanding	-	-	0	-	-	-	0	-	-	-	0	-
Preferred Stock Liquidation Preference Value	-	-	50	-	-	-	50	-	-	-	50	-
Common Stock Par Or Stated Value Per Share	-	-	0.1	-	-	-	0.1	-	-	-	0.1	-
Common Stock Shares Authorized	-	-	4,500	-	-	-	4,500	-	-	-	4,500	-
Common Stock Shares Issued	-	-	2,900	-	-	-	2,900	-	-	-	2,900	-
Treasury Stock Common Shares	-	-	887	-	-	-	894	-	-	-	902	-

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-1.86%	-10.88%	1.38%	-	-	-	-	-	-	-	-	-
2025	-3.98%	2.18%	-2.49%	10.64%	3.95%	2.12%	1.38%	18.79%	22.56%	0.60%	0.47%	-1.85%
2024	-1.50%	-7.83%	-8.11%	-2.16%	-2.62%	4.63%	5.56%	2.80%	2.05%	8.80%	-0.45%	-8.96%
2023	-	-	-	-	-	-	-4.02%	-3.93%	-3.92%	10.43%	6.58%	-8.64%
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	1.53	1.42	1.26	1.27	1.21	1.28	1.25	1.24	1.16	1.11	1.43	1.18
Quick Ratio	1.38	1.28	1.14	1.17	1.11	1.17	1.15	1.09	1.02	0.99	1.31	1.07
Working Capital	9.92B	8.05B	5.97B	7.49B	5.69B	6.71B	6.01B	5.44B	3.63B	2.85B	9.51B	4.17B
Leverage & Debt
Debt to Equity	2.93	3.31	3.87	4.21	4.41	4.30	4.67	4.46	4.54	5.00	2.23	2.14
Debt Ratio	0.75	0.77	0.79	0.81	0.82	0.81	0.82	0.82	0.82	0.83	0.69	0.68
Efficiency & Turnover
Asset Turnover TTM	0.54	0.54	0.53	0.50	0.50	0.50	0.51	0.51	0.49	0.47	0.47	0.47
Days Sales Outstanding TTM	81.51	75.92	83.92	85.29	87.37	81.40	81.87	82.06	84.50	82.17	84.37	80.89
Receivables Turnover TTM	4.48	4.81	4.35	4.28	4.18	4.48	4.46	4.45	4.32	4.44	4.33	4.51
Per Share Metrics
Diluted EPS TTM	4.53	3.55	3.46	2.96	2.48	2.66	-4.41	-3.57	-3.22	-3.03	3.87	4.02
Free Cash Flow Per Share TTM	5.60	5.84	6.32	7.52	7.16	6.44	6.88	6.81	6.39	6.18	6.11	5.68
Dividend Per Share TTM	2.50	2.49	2.48	2.46	2.43	2.42	2.40	2.37	2.36	2.35	2.29	2.30
Margin Metrics
Gross Profit Margin TTM	70.16%	70.46%	71.08%	69.50%	70.29%	70.47%	71.08%	74.91%	75.38%	75.71%	76.24%	76.54%
Operating Profit Margin TTM	24.21%	19.79%	19.36%	16.72%	13.82%	12.82%	-17.35%	-14.50%	-13.80%	-12.84%	18.75%	19.19%
Net Profit Margin TTM	18.87%	15.01%	14.64%	12.58%	10.61%	11.41%	-18.49%	-15.27%	-14.04%	-13.48%	17.86%	18.46%
Growth Metrics
Net Revenue Growth (1Y)	3.11%	1.78%	-0.22%	1.26%	2.57%	4.62%	7.32%	5.56%	2.93%	-0.68%	-2.50%	-3.86%
Net Income Growth (1Y)	83.29%	33.90%	-178.97%	-183.42%	-177.52%	-188.53%	-211.11%	-187.34%	-181.92%	-183.90%	27.07%	23.85%
EPS Growth (1Y)	82.66%	33.44%	-178.69%	-183.09%	-177.22%	-188.18%	-213.41%	-188.59%	-184.59%	-187.05%	30.82%	28.42%
Valuation Metrics
P/E TTM	12.54	16.63	15.05	14.50	17.52	21.24	-11.83	-13.20	-11.57	-15.86	11.58	12.50
P/B TTM	5.21	6.03	5.75	4.71	5.07	6.61	6.47	5.58	4.43	5.90	3.16	3.57
P/S TTM	2.37	2.50	2.20	1.82	1.86	2.42	2.19	2.02	1.62	2.14	2.07	2.31
Market Cap	116.35B	120.98B	106.13B	87.62B	88.72B	115.41B	105.65B	95.62B	75.57B	97.35B	93.12B	103.67B
Enterprise Value	150.74B	155.85B	141.02B	120.87B	125.29B	154.24B	144.95B	137.48B	121.66B	143.69B	121.37B	133.71B
Calculated Values
Free Cash Flow TTM	11.44B	11.91B	12.85B	15.30B	14.58B	13.09B	13.94B	13.80B	12.95B	12.51B	12.65B	11.69B
Net Debt	34.40B	34.88B	34.89B	33.25B	36.57B	38.84B	39.30B	41.86B	46.09B	46.34B	28.25B	30.04B
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-04-01Sale

Owner: Elkins, David V

Title: EVP, Chief Financial Officer

Shares: 30,000

Price/Share: $61.82

Value: $1,854,600.00

Shares Owned: 159,248

Relationship: Officer

Ownership: Direct

2025-09-02Sale

Owner: Elkins, David V

Title: EVP, Chief Financial Officer

Shares: 56,000

Price/Share: $47.33

Value: $2,650,480.00

Shares Owned: 167,379

Relationship: Officer

Ownership: Direct

2025-08-02Sale

Owner: Short, Bartie Wendy

Title: EVP, Corporate Affairs

Shares: 378

Price/Share: $44.23

Value: $16,718.94

Shares Owned: 5,066

Relationship: Officer

Ownership: Direct

2025-05-09Sale

Owner: Hickey, Benjamin

Title: President, RayzeBio Org.

Shares: 97

Price/Share: $38.01

Value: $3,701.79

Shares Owned: -

Relationship: Officer

Ownership: Indirect

2025-04-25Purchase

Owner: Hirawat, Samit

Title: EVP,Chief Med.Offr.,Drug Dev.

Shares: 4,250

Price/Share: $47.58

Value: $202,215.00

Shares Owned: 83,513

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-04-01	Elkins, David V	Officer	EVP, Chief Financial Officer	Direct	Sale	30,000	61.82	$1,854,600.00	159,248	4
2025-09-02	Elkins, David V	Officer	EVP, Chief Financial Officer	Direct	Sale	56,000	47.33	$2,650,480.00	167,379	4
2025-08-02	Short, Bartie Wendy	Officer	EVP, Corporate Affairs	Direct	Sale	378	44.23	$16,718.94	5,066	4
2025-05-09	Hickey, Benjamin	Officer	President, RayzeBio Org.	Indirect	Sale	97	38.01	$3,701.79	0	4
2025-04-25	Hirawat, Samit	Officer	EVP,Chief Med.Offr.,Drug Dev.	Direct	Purchase	4,250	47.58	$202,215.00	83,513	4
2025-02-20	Boerner, Christopher S.	Director,Officer	Chief Executive Officer	Direct	Purchase	2,000	55.05	$110,100.00	104,626	4
2025-02-14	Hirawat, Samit	Officer	EVP,Chief Med.Offr.,Drug Dev.	Direct	Purchase	1,823	54.84	$100,000.19	63,932	4
2024-11-04	Holzer, Phil M	Officer	SVP and Controller	Direct	Sale	700	55.62	$38,934.00	11,760	4
2024-11-01	Hirawat, Samit	Officer	EVP,Chief Med.Offr.,Drug Dev.	Direct	Purchase	1,830	54.68	$100,064.40	62,109	4
2023-12-05	Boerner, Christopher S.	Officer	Chief Executive Officer	Direct	Purchase	2,000	49.78	$99,560.00	82,672	4
2023-11-28	Boerner, Christopher S.	Officer	Chief Executive Officer	Direct	Purchase	3,071	48.86	$150,049.06	79,384	4
2023-11-20	Samuels, Theodore R. Ii	Director	-	Direct	Purchase	8,500	49.81	$423,385.00	35,500	4
2023-08-24	Powell, Ann	Officer	EVP, Chief Human Resources	Direct	Sale	17,986	61.25	$1,101,642.50	27,868	4
2023-08-03	Plenge, Robert M	Officer	EVP, Chief Research Officer	Direct	Sale	732	61.14	$44,754.48	6,584	4
2023-05-03	Vessey, Rupert	Officer	EVP & President, Research	Direct	Sale	50,385	67.06	$3,378,818.10	47,751	4
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

70.44%

Inst. Shares: 1,435,643,223

Shares Outstanding: 2,038,000,000

2025-12-31

76.38%

Inst. Shares: 1,553,619,206

Shares Outstanding: 2,034,000,000

2025-09-30

74.40%

Inst. Shares: 1,514,785,863

Shares Outstanding: 2,036,000,000

2025-06-30

77.00%

Inst. Shares: 1,566,889,783

Shares Outstanding: 2,035,000,000

2025-03-31

75.02%

Inst. Shares: 1,523,659,112

Shares Outstanding: 2,031,000,000

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	1,435,643,223	2,038,000,000	70.44%
2025-12-31	1,553,619,206	2,034,000,000	76.38%
2025-09-30	1,514,785,863	2,036,000,000	74.40%
2025-06-30	1,566,889,783	2,035,000,000	77.00%
2025-03-31	1,523,659,112	2,031,000,000	75.02%
2024-12-31	1,516,652,401	2,027,000,000	74.82%
2024-09-30	1,422,342,997	2,028,000,000	70.14%
2024-06-30	1,445,281,334	2,027,000,000	71.30%
2024-03-31	1,431,199,849	2,023,000,000	70.75%
2023-12-31	1,463,928,941	2,069,000,000	70.76%
2023-09-30	1,463,214,648	2,057,000,000	71.13%
2023-06-30	1,483,472,300	2,093,000,000	70.88%
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

BRISTOL MYERS SQUIBB CO (BMY) — SEC Financial Statements & Analysis

BRISTOL MYERS SQUIBB CO (BMY) is a pharmaceutical preparations company, incorporated in DE. BRISTOL MYERS SQUIBB CO trades on NYSE as: BMY, CELG-RI. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), BRISTOL MYERS SQUIBB CO reported a 3.11% year-over-year revenue growth, a Gross Profit Margin of 70.16% (TTM), a Debt-to-Equity ratio of 2.93x, a Price-to-Sales (P/S) ratio of 2.37x (TTM), a Price-to-Book (P/B) ratio of 5.21 (TTM), at a market cap of $116.35B. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 3.11%
Gross Profit Margin TTM: 70.16%
Debt To Equity: 2.93x
P/S TTM: 2.37x
P/B TTM: 5.21
Market Cap: $116.35B

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is BRISTOL MYERS SQUIBB CO in?

BRISTOL MYERS SQUIBB CO (BMY) operates in the Pharmaceutical Preparations industry.

What is BMY's market cap?

BRISTOL MYERS SQUIBB CO (BMY) has a market capitalization of $116.35B as of 2026-06-30.

What is BMY's P/E ratio?

BRISTOL MYERS SQUIBB CO (BMY)'s trailing twelve month P/E ratio is 12.54x as of 2026-06-30.

What exchange does BMY trade on?

BRISTOL MYERS SQUIBB CO (BMY) trades on the NYSE.

Where is BRISTOL MYERS SQUIBB CO incorporated?

BRISTOL MYERS SQUIBB CO is incorporated in DE.

BRISTOL MYERS SQUIBB CO (BMY) — SEC Financial Statements & Analysis

Frequently Asked Questions

Research Faster.Invest Smarter.

Research Faster.
Invest Smarter.